NUZ Shares Neurizon Therapeutics Limited
STRONG BUY ASX · ASXPositive FDA pathway feedback materially improves development visibility for its ALS candidate.
Future value: $0.20 (+132.56%) · 6-12 months
Signal breakdown
- ▸FDA feedback supported speculative buy recommendation
- ▸Above 50-day MA (+16.97%)
- ▸Above 200-day MA — long-term uptrend
- ▸~133% upside to price target
Is NUZ a buy right now?
Trend: NUZ is trading above the 50-day average (+28.57%), RSI 37 — neutral momentum, with a 3-month return of +51.26%.
Valuation & quality: Neurizon Therapeutics Limited trades on PEG 0.76, price-to-book 5.29; fundamentals show net margin -61.0%, return on equity -137.9%, revenue growth 181460.9% year on year.
Analyst consensus: 2 analysts have a mean 12-month price target of A$0.48 (+464% vs the last close; range A$0.20 – A$0.77), consensus rating “none”.
Our screen: STRONG BUY (score 5) — Positive FDA pathway feedback materially improves development visibility for its ALS candidate.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -11.10% | +0.00% | -25.00% | +0.00% | +0.00% | +0.00% | +33.30% | +12.50% |
Fundamentals
Analyst price target
Technical signals
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.